Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer

BACKGROUND: Markers to predict the efficacy of bevacizumab treatment have been not fully validated in most cancers, including metastatic colorectal cancer (mCRC). The aim of this study was to investigate the potential role of lactate dehydrogenase (LDH) in predicting the survival benefit from first-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yin, Chenxi, Jiang, Chang, Liao, Fangxin, Rong, Yuming, Cai, Xiuyu, Guo, Guifang, Qiu, Huijuan, Chen, Xuxian, Zhang, Bei, He, Wenzhuo, Xia, Liangping
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2014
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4136961/
https://ncbi.nlm.nih.gov/pubmed/25143746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S64559
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge